SV2A and Alzheimer disease: In the diagnosis of AD, the AUCs of the diagnostic models combining serum NfL, GFAP, and p-tau217 with serum SV2A were improved to 88.3%, 93.7%, and 94.2%, respectively, which were significantly higher than the AUCs of these biomarkers when used alone (p < 0.01).